MicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirin.

ABSTRACT: It has been demonstrated that microRNA-122 (miR-122) plays key roles in the modulation of hepatitis B virus (HBV) replication. This study examined the role of miR-122 in patients with hepatitis C virus (HCV)-HBV dual infection with active hepatitis C who received pegylated interferon-? and ribavirin dual therapy. We enrolled 121 patients with HCV-HBV dual infection after dual therapy. Stored serum was collected before treatment. RT-PCR was used to analyze miR-122. HBsAg seroclearance was noted in 37 (30.1%) cases during a median follow-up period of 5.4?years. miR-122 was significantly lower in HBsAg seroclearance patients than in non-HBsAg seroclearance patients (P??100?IU/mL versus ?100?IU/mL (P?

SUBMITTER: Yen YH 

PROVIDER: S-EPMC5036026 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature